MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 333056 | Name: Viloxazine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Viloxazine, also known as SPN-812, is aselective norepinephrine reuptake inhibitor (NRI). Viloxazine was approved for medical use in the United States in April 2021 to treat attention deficit hyperactivity disorder (ADHD). Viloxazine, like imipramine, inhibited norepinephrine reuptake in the hearts of rats and mice; unlike imipramine, it did not block reuptake of norepinephrine in either the medullae or the hypothalami of rats. As for serotonin, while its reuptake inhibition was comparable to that of desipramine (i.e., very weak), viloxazine did potentiate serotonin-mediated brain functions in a manner similar to amitriptyline and imipramine, which are relatively potent inhibitors of serotonin reuptake. Unlike any of the other drugs tested, it did not exhibit any anticholinergic effects.

Chemical Structure

Viloxazine HCl
Viloxazine HCl
CAS#35604-67-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 333056

Name: Viloxazine HCl

CAS#: 35604-67-2 (HCl)

Chemical Formula: C13H20ClNO3

Exact Mass: 0.0000

Molecular Weight: 273.76

Elemental Analysis: C, 57.04; H, 7.36; Cl, 12.95; N, 5.12; O, 17.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
35604-67-2 (HCl) 46817-91-8 (free base) 21949-60-0 (acetate)
Synonym
Viloxazine HCl; ICI 58,834; ICI-58,834; ICI58,834; ICI 58834; ICI-58834; ICI58834; SPN-812; SPN 812; SPN812;
IUPAC/Chemical Name
2-((2-ethoxyphenoxy)methyl)morpholine hydrochloride
InChi Key
HJOCKFVCMLCPTP-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
SMILES Code
CCOC1=CC=CC=C1OCC2OCCNC2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 273.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2021 Feb 17. doi: 10.1089/cap.2020.0148. Epub ahead of print. PMID: 33600233. 2: Faison SL, Fry N, Adewole T, Odebo O, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):155-162. doi: 10.1097/JCP.0000000000001361. PMID: 33587403; PMCID: PMC7919699. 3: Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 2021 Feb;296:113664. doi: 10.1016/j.psychres.2020.113664. Epub 2021 Jan 5. PMID: 33418457. 4: Faison SL, Fry N, Adewole T, Odebo O, Schwabe S, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clin Drug Investig. 2021 Feb;41(2):149-159. doi: 10.1007/s40261-020-00992-6. Epub 2020 Dec 23. PMID: 33368026; PMCID: PMC7886742. 5: Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, Kleiman RB, Schwabe S. Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. J Clin Psychiatry. 2020 Oct 13;81(6):20m13395. doi: 10.4088/JCP.20m13395. PMID: 33049804.

View History

Fosravuconazole monolysine

Fosravuconazole monolysine